Clozapine vs Quetiapine (Seroquel XR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Clozapine

Marketed by HLS Therapeutics Inc.

Approved in Schizophreniasmall molecule
Weak signal

NCT00250575 · Phase 3 · completed

The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.

Next expected readout: April 2027 · NCT04580134 (registry estimate)

Reported efficacy

Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)

Result source: NCT03510325

Quetiapine (Seroquel XR)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Weak signal

NCT00640601 · Phase 3 · completed

This was a nonrandomized, single-group, open-label study of 295 treated participants, without a placebo or active comparator. Although 56.88% were reported to have improved clinical benefit on the primary CGI-CB measure, the uncontrolled design cannot determine how much of the improvement was due to quetiapine rather than other factors.

Next expected readout: February 2032 · NCT07152184 (registry estimate)

Reported efficacy

Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8) (not_applicable)

Result source: NCT00640601

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointClozapineQuetiapine (Seroquel XR)
PANSS total, change—Not posted · NCT00649844-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • 102.3 vs 100.5 wk 12 · n 107 · Phase 3 · secondary NCT00640562
CGI-S, change—Not posted · NCT00649844-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.5 vs -1.0 wk 12 · n 107 · Phase 3 · secondary NCT00640562
PANSS response—Not posted · NCT0064984462.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380
PSP, change—Not posted · NCT0064984415.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380
Relapse (% of patients)—Not posted · NCT00649844—Not posted · NCT00159770

PANSS total, change

Clozapine
—Not posted · NCT00649844
Quetiapine (Seroquel XR)
-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • 102.3 vs 100.5 wk 12 · n 107 · Phase 3 · secondary NCT00640562

CGI-S, change

Clozapine
—Not posted · NCT00649844
Quetiapine (Seroquel XR)
-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.5 vs -1.0 wk 12 · n 107 · Phase 3 · secondary NCT00640562

PANSS response

Clozapine
—Not posted · NCT00649844
Quetiapine (Seroquel XR)
62.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380

PSP, change

Clozapine
—Not posted · NCT00649844
Quetiapine (Seroquel XR)
15.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380

Relapse (% of patients)

Clozapine
—Not posted · NCT00649844
Quetiapine (Seroquel XR)
—Not posted · NCT00159770
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Clozapine: 3 of 4 rows · Quetiapine (Seroquel XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricClozapineQuetiapine (Seroquel XR)
Dropout rate
41.7%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT00498550 · Phase 4 · registry result, not featured evidence
17.2%
NCT02404155 · Phase na · registry result, not featured evidence
38%a
NCT00640601 · Phase 3
show 7 more results
16.5%
NCT00640562 · Phase 3
—Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
20%
NCT00954122 · Phase 4 · registry result, not featured evidence
30.2%
NCT00779506 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
20.8%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
—
NCT00498550 · Phase 4 · registry result, not featured evidence
—
NCT02404155 · Phase na · registry result, not featured evidence
14.6%a
NCT00640601 · Phase 3
show 7 more results
7.3%
NCT00640562 · Phase 3
—Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
2.9%
NCT00954122 · Phase 4 · registry result, not featured evidence
4.2%
NCT00779506 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
2.6%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Serious AEs
13%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
26.7%
NCT00498550 · Phase 4 · registry result, not featured evidence
6.9%
NCT02404155 · Phase na · registry result, not featured evidence
11.2%a
NCT00640601 · Phase 3
show 7 more results
3.7%
NCT00640562 · Phase 3
0%Seroquel IR
NCT01213836 · Phase 4 · registry result, not featured evidence
0%Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
2.9%
NCT00954122 · Phase 4 · registry result, not featured evidence
0%
NCT00779506 · Phase 4 · registry result, not featured evidence
1.3%Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
—Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
other-sialorrhea 43.5%
weight gain 30.4%
sedation 21.7%
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
gastrointestinal disorder - other: hypersalivation 66.7%
somnolence 60%
weight gain 40%
NCT00498550 · Phase 4 · registry result, not featured evidence
salivation 68.2%
sedation 52.9%
malaise 52.6%
NCT02404155 · Phase na · registry result, not featured evidence
a
somnolence 18%
dizziness 14.6%
sedation 14.2%
NCT00640601 · Phase 3
show 5 more results
somnolence 5.5%
dry months 4.6%
hypotension 4.6%
NCT00640562 · Phase 3
somnolence 3.2%
delusion 1.6%
dizziness 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
psychotic disorder 1.6%
sedation 1.6%
sleep disorder 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
constipation 25.5%
insomnia 23.4%
sedation 12.8%
NCT00779506 · Phase 4 · registry result, not featured evidence
somnolence 22.2% (placebo 5%)
weight increased 13.1% (placebo 3.7%)
dizziness 11.8% (placebo 0.6%)
NCT01810380 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Clozapine

Cannabis Use Intensity Joints Per 2.36 vs 2.35 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 10.21 weeks as posted
Cannabis Use Frequency Days Per 0.14 vs 0.15 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 4.26 days as posted
Cannabis Use Joints Per 0.02 per week
absolute value · per week
No placebo or comparator arm
NCT00498550 · Phase 4 · registry result, not featured evidence

Quetiapine (Seroquel XR)

Clinical Benefit 56.88% (n=295) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT00640601 · Phase 3
CGI-CB 1.41 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
PANSS Total 10.95 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 2 more results
-33.2 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence
-26.8 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
PANSS Positive 2.36 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 1 more result
-7.4 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
PANSS Negative 3.67 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 1 more result
-6.2 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
GAS 5.54 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
CGI-S 0.51 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 2 more results
-1.2 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence
-1.46 score @ 8.14wk
NCT00779506 · Phase 4 · registry result, not featured evidence
CGI-I 0.55 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
show 1 more result
2.4 score @ 3wk
NCT00954122 · Phase 4 · registry result, not featured evidence
SOFAS 6.45 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00640601 · Phase 3
CDSS 7.31 vs 5.53 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
HAM-D -29.83 vs -23.02 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
PANSS Total 102.26 vs 100.51 Risperidone score @ 12wk
absolute change · score
NCT00640562 · Phase 3
show 1 more result
-24 vs -15.9 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence

+ 22 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Quetiapine (Seroquel XR)'s landscape